Spots Global Cancer Trial Database for Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Official Title: Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.
Study ID: NCT00394446
Conditions
Interventions
Study Description
Brief Summary: Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Contact Details
Name: Margaret Yu, MD
Affiliation: Myrexis Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
